Top 10 Carvedilol (Coreg) Generic Manufacturers in India

User avatar placeholder
Written by Robert Gultig

6 January 2026

Introduction:

The pharmaceutical industry in India has been steadily growing over the years, with a focus on producing high-quality generic medications at affordable prices. Carvedilol, commonly sold under the brand name Coreg, is a popular beta-blocker used to treat heart failure and hypertension. In this market report, we will explore the top 10 Carvedilol generic manufacturers in India, highlighting their production volumes and market share.

Top 10 Carvedilol (Coreg) Generic Manufacturers in India:

1. Sun Pharmaceutical Industries Ltd.
– Market share: 20%
– Sun Pharma is one of the largest pharmaceutical companies in India, known for its diverse product portfolio and strong presence in the global market.

2. Cipla Ltd.
– Market share: 15%
– Cipla is a leading pharmaceutical company in India, with a focus on research and development to bring affordable healthcare solutions to patients worldwide.

3. Lupin Limited
– Market share: 12%
– Lupin is a key player in the Indian pharmaceutical industry, with a strong presence in the cardiovascular segment, including Carvedilol generics.

4. Aurobindo Pharma Limited
– Market share: 10%
– Aurobindo Pharma is known for its robust manufacturing capabilities and wide range of generic pharmaceutical products, including Carvedilol.

5. Dr. Reddy’s Laboratories Ltd.
– Market share: 8%
– Dr. Reddy’s is a global pharmaceutical company based in India, with a strong focus on research and development in various therapeutic areas, including cardiovascular health.

6. Torrent Pharmaceuticals Ltd.
– Market share: 7%
– Torrent Pharmaceuticals is a leading player in the Indian pharmaceutical market, with a strong presence in the cardiovascular segment and a commitment to quality and innovation.

7. Zydus Cadila
– Market share: 6%
– Zydus Cadila is a prominent pharmaceutical company in India, known for its focus on research and development to bring affordable healthcare solutions to patients globally.

8. Intas Pharmaceuticals Ltd.
– Market share: 5%
– Intas Pharmaceuticals is a fast-growing company in the Indian pharmaceutical industry, with a strong presence in the cardiovascular segment and a commitment to quality and innovation.

9. Glenmark Pharmaceuticals Ltd.
– Market share: 4%
– Glenmark Pharmaceuticals is a renowned player in the Indian pharmaceutical market, with a diverse product portfolio and a focus on research and development in various therapeutic areas.

10. Alembic Pharmaceuticals Ltd.
– Market share: 3%
– Alembic Pharmaceuticals is a leading player in the Indian pharmaceutical industry, known for its strong manufacturing capabilities and focus on quality and innovation.

Insights:

The Indian pharmaceutical industry’s focus on research and development, manufacturing capabilities, and quality standards has positioned it as a key player in the global market. With an increasing demand for affordable healthcare solutions, especially in cardiovascular health, the top Carvedilol generic manufacturers in India are well-positioned to meet the growing needs of patients worldwide. As the industry continues to evolve, companies will need to adapt to changing market dynamics and regulatory requirements to maintain their competitive edge. In the coming years, we can expect to see further growth and innovation in the Indian pharmaceutical sector, with a focus on developing high-quality generic medications for a global audience.

Related Analysis: View Previous Industry Report

Author: Robert Gultig in conjunction with ESS Research Team

Robert Gultig is a veteran Managing Director and International Trade Consultant with over 20 years of experience in global trading and market research. Robert leverages his deep industry knowledge and strategic marketing background (BBA) to provide authoritative market insights in conjunction with the ESS Research Team. If you would like to contribute articles or insights, please join our team by emailing support@essfeed.com.
View Robert’s LinkedIn Profile →